Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 896 shares, a decline of 70.1% from the September 30th total of 2,997 shares. Based on an average trading volume of 879 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.4% of the shares of the company are sold short.
Amplify Weight Loss Drug & Treatment ETF Stock Up 2.6%
Shares of THNR stock traded up $0.65 during trading on Thursday, reaching $25.36. 849 shares of the company’s stock were exchanged, compared to its average volume of 1,802. The stock has a market capitalization of $5.83 million, a PE ratio of 24.31 and a beta of 0.42. Amplify Weight Loss Drug & Treatment ETF has a twelve month low of $22.89 and a twelve month high of $27.94. The firm’s fifty day moving average price is $25.64 and its 200-day moving average price is $25.34.
About Amplify Weight Loss Drug & Treatment ETF
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Further Reading
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
